Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Companyâs lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Companyâs pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļāļ·āđāļāļāļĢāļīāļĐāļąāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒ- -
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļ- -
āļāļĩāđāļāļĒāļđāđ- -
āđāļĄāļ·āļāļ- -
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđ- -
āļāļĢāļ°āđāļāļĻ- -
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ- -
āđāļ§āđāļāđāļāļāđ- -
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
Mr. Timothy P. (Tim) Noyes
Mr. Timothy P. (Tim) Noyes
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
Mr. Mark Iwicki
Independent Director
Ms. Allison Dorval, CPA
Independent Director
Dr. Joshua Resnick, M.D.
Independent Director
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Mr. Stephen K. Yu
Senior Vice President - Quality
Senior Vice President - Quality
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
Mr. Timothy P. (Tim) Noyes
Mr. Timothy P. (Tim) Noyes
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
Mr. Mark Iwicki
Independent Director
Ms. Allison Dorval, CPA
Independent Director
Dr. Joshua Resnick, M.D.
Independent Director